about
Targeted drug delivery via folate receptors in recurrent ovarian cancer: a reviewChemotherapy in elderly patients with gynecological cancer.Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.Thrombotic thrombocytopenic purpura during pregnancy versus imitator of preeclampsia.Fertility drugs, reproductive strategies and ovarian cancer risk.Lack of association between serotonin transporter 5-HTT gene polymorphism and endometriosis in an Italian patient populationAre mood and anxiety disorders and alexithymia associated with endometriosis? A preliminary study.Characterization of human vaginal mucosa cells for autologous in vitro cultured vaginal tissue transplantation in patients with MRKH syndrome.Topical KGF treatment as a therapeutic strategy for vaginal atrophy in a model of ovariectomized mice.Angiogenesis and antiangiogenic agents in cervical cancer.Discovery of chemotherapy-associated ovarian cancer antigens by interrogating memory T cells.Gene expression profile of patients with Mayer-Rokitansky-Küster-Hauser syndrome: new insights into the potential role of developmental pathways.Restoring vaginal microbiota: biological control of bacterial vaginosis. A prospective case-control study using Lactobacillus rhamnosus BMX 54 as adjuvant treatment against bacterial vaginosis.Current status of bevacizumab in advanced ovarian cancerVulvar malignancy in neurofibromatosis syndromeIs CA72-4 a useful biomarker in differential diagnosis between ovarian endometrioma and epithelial ovarian cancer?Impaired uterine artery flow associated with the presence of ovarian endometrioma: preliminary results of a prospective study.Endometrial marginal zone B-cell MALT-type lymphoma: case report and literature review.Beyond bevacizumab: investigating new angiogenesis inhibitors in ovarian cancer.Investigating molecular profiles of ovarian cancer: an update on cancer stem cells.Surgical treatment of an isolated omental cervical cancer recurrence: report of a case and review of the literature.Correlation between fertility drugs use and malignant melanoma incidence: the state of the art.Emergency peripartum hysterectomy in a tertiary teaching hospital: a 14-year review.Surgical Treatment of Recurrent Endometrial Cancer: Time for a Paradigm Shift.Advances in anti-angiogenic agents for ovarian cancer treatment: The role of trebananib (AMG 386).Prognostic role of inguinal lymphadenectomy in vulvar squamous carcinoma: younger and older patients should be equally treated. A prospective study and literature review.Perivascular epithelioid cell neoplasm (PEComa) of the uterus: A systematic review.An overview of early investigational therapies for chemoresistant ovarian cancer.Continuous versus cyclic oral contraceptives after laparoscopic excision of ovarian endometriomas: a systematic review and metaanalysis.Bilateral risk-reduction mastectomy in BRCA1 and BRCA2 mutation carriers: a meta-analysis.Does extensive upper abdomen surgery during primary cytoreduction impact on long-term quality of life?Secondary analyses from a randomized clinical trial: age as the key prognostic factor in endometrial carcinoma.Microvesicle cargo of tumor-associated MUC1 to dendritic cells allows cross-presentation and specific carbohydrate processing.Dualistic classification of epithelial ovarian cancer: surgical and survival outcomes in a large retrospective series.Preliminary results of a triple peptide escalating dose vaccination phase I/II clinical trial as consolidation treatment in women affected by ovarian cancer.Effects of unilateral ovariectomy on female fertility outcome.Benign schwannoma in supraclavicular region: a false-positive lymph node recurrence of breast cancer suspected by PET scan.Quality of life in patients with endometrial cancer treated with or without systematic lymphadenectomy.Dose-Dense Neoadjuvant Chemotherapy plus Radical Surgery in Locally Advanced Cervical Cancer: A Phase II Study.Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial.
P50
Q26828581-4610C65A-AE90-489A-8161-43FA85189CB1Q33410185-816FC86E-3FC5-4809-ABDB-0B275ADD047FQ33413609-D50016DB-A634-4F2B-BFD4-A88F82754B66Q33425102-39D65D92-7CEE-4968-9DA6-972CAAC091D6Q33608317-DCAAEE0F-8429-4D44-AB7F-E551B164E5D7Q33790869-AFFDB60A-8744-402F-A179-210C3D917F9CQ33876231-8DEE3324-B171-414C-ABE9-5CC8E15C9EC5Q34069635-25AC5344-1A74-42F7-96C3-A1AD3551CF15Q34336891-1668494E-7A0F-48A1-ADC1-F886726CC9CCQ34655335-4A000D2F-A7B7-418E-A576-DDC8693EC62FQ35024484-CB985661-929B-4AAD-A256-D77DB782A3A8Q35114881-8CB6E4FD-BCA7-4A60-A8BB-4FE6752CD8B9Q35682766-9C02AF44-BD54-4E0C-AFA9-6F3199A6B2DDQ37048186-37894C7F-8586-47D9-9303-2421AFEAA788Q37220286-A44E0852-9045-4FC2-B156-EA5A62214E4DQ37221882-72358B99-D6A7-44E9-B2B6-918DF7A526CAQ37509888-A98A1B36-2EA0-499F-8786-426DEE9C5083Q38117986-5F7A30B3-93DE-45DF-967D-87C6112A9411Q38151193-6248DF52-649C-436B-A35B-B0D5528D83EDQ38203882-FF0A6ECE-8CC9-41A2-9F17-1F0814C9567FQ38213889-F46ACBF1-00E6-4067-8DE9-BD756EB52798Q38223603-9EB95196-B8E1-4BAC-A4B7-F2F0FB418C10Q38254075-EDFC0F9A-BB32-4416-9273-7ED51596371DQ38380255-5E87BCDA-2D7A-46D9-9E24-645A41992AF8Q38382072-50823BED-86A8-4C28-A6B2-C0C4CFFBF6ADQ38426654-57D9499D-B10F-4977-A077-0427413387E7Q38485072-31B69A36-63F0-4873-A21E-FE06624655C0Q38553247-85F7D847-D128-43CA-9FAA-42AC0F4A7255Q38585908-B7862852-FCFC-4AE1-A195-5A13C5D82CD2Q41161920-006B6DC0-C058-4D3C-A934-203378003B3FQ44047853-B0FDD9B8-3D7C-4E49-B2FC-F2E3EB7427E1Q44247526-3F2702EF-9EAD-40FA-A6B9-CE209127B48EQ44839641-D2ED358C-DBE9-4F39-AF12-0703893F59F3Q45906655-2A4792E4-D0A3-4B78-B3C4-C6ECA6302CEEQ46579517-E8B7F5D6-8BD4-43E7-85FA-8792826007CFQ47822785-80FECB43-6F12-4E88-8A93-FD2788E14FB7Q47882253-3C6AC220-7910-47F7-B940-D7757CC913BEQ48189366-D2031191-CB1F-4972-9761-2625D4F5AA2CQ49086612-81D727DC-5181-4E6E-B62C-1583CC1BEE71Q50564383-152A71A7-4B92-4E6F-8F60-F724C47C56A0
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Pierluigi Benedetti Panici
@ast
Pierluigi Benedetti Panici
@en
Pierluigi Benedetti Panici
@es
Pierluigi Benedetti Panici
@nl
Pierluigi Benedetti Panici
@sl
type
label
Pierluigi Benedetti Panici
@ast
Pierluigi Benedetti Panici
@en
Pierluigi Benedetti Panici
@es
Pierluigi Benedetti Panici
@nl
Pierluigi Benedetti Panici
@sl
prefLabel
Pierluigi Benedetti Panici
@ast
Pierluigi Benedetti Panici
@en
Pierluigi Benedetti Panici
@es
Pierluigi Benedetti Panici
@nl
Pierluigi Benedetti Panici
@sl
P106
P21
P31
P496
0000-0001-6752-2039